SOLVE ON.

Incyte Provides Updated Statement on Response to COVID-19

WILMINGTON, Del., March 30, 2020 – As a global biopharmaceutical company, Incyte takes public health very seriously, and we are closely monitoring the evolving COVID-19 pandemic.

Our teams are rapidly evaluating randomized trials aimed at studying ruxolitinib (Jakafi®) as a potential treatment for patients with COVID-19 associated cytokine storm. Additionally, through our Investigator Initiated Research (IIR) program, we are expediting review of requests for ruxolitinib made by U.S. investigators and evaluating requests for our other compounds globally. Outside of the United States, our partners at Novartis are similarly evaluating requests for ruxolitinib (Jakavi®) through their managed access process.

The Incyte IIR program is open to physicians, researchers and institutions interested in conducting external research. For questions or inquiries, please contact:

United States
US_IIR@incyte.com

Outside the United States
Global_IIR@incyte.com

At present, we have ample commercial and clinical supply of our medicines to meet the needs of patients receiving our approved medicines and those participating in our global clinical trials. The global COVID-19 outbreak has not had any impact on Incyte's supply chain and we are working diligently to increase our manufacturing efforts in response to the COVID-19 pandemic.

Our primary focus is on ensuring patients have access to the medicines they need while safeguarding the health and safety of our employees. During these unprecedented times, we send our gratitude to the many healthcare providers on the frontlines of this outbreak, and our support to all those affected by this virus.

Inquiries about Incyte products or company-sponsored clinical trials can be made to Incyte Medical Information:

United States
1-855-4MED-INFO (855-463-3463)
medinfo@incyte.com

Outside the United States
+800 00027423
globalmedinfo@incyte.com
eumedinfo@incyte.com
View country-specific contact information here.

SOLVE ON.

About Jakafi® (ruxolitinib)

Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. FDA for treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.
Jakafi is also indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea as well as adults with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi® (ruxolitinib) outside the United States. Jakafi is a registered trademark of Incyte Corporation. Jakavi is a registered trademark of Novartis AG in countries outside the United States.

For full product information visit www.incyte.com.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

###

Incyte Contacts

Media

Catalina Loveman +1 302 498 6171
cloveman@incyte.com

Jenifer Antonacci +1 302 498 7036
jantonacci@incyte.com

Ela Zawislak +41 21 343 31 13
Ezawislak@incyte.com

Investors

Michael Booth, DPhil +1 302 498 5914
mbooth@incyte.com